Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been given a consensus recommendation of “Moderate Buy” by the twelve research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $19.8750.

JSPR has been the subject of a number of research analyst reports. Rodman & Renshaw assumed coverage on Jasper Therapeutics in a report on Tuesday, January 13th. They set a “buy” rating and a $17.00 price target for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Thursday, January 22nd.

Jasper Therapeutics Trading Down 4.2%

Shares of NASDAQ:JSPR opened at $1.38 on Thursday. The firm has a 50 day moving average of $1.69 and a 200-day moving average of $2.21. Jasper Therapeutics has a 12 month low of $1.33 and a 12 month high of $7.19. The stock has a market capitalization of $38.61 million, a PE ratio of -0.23 and a beta of 3.08.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.12). On average, research analysts predict that Jasper Therapeutics will post -4.47 EPS for the current fiscal year.

Institutional Trading of Jasper Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC acquired a new position in shares of Jasper Therapeutics during the first quarter worth $46,000. Marex Group plc bought a new position in Jasper Therapeutics during the 2nd quarter worth $74,000. Engineers Gate Manager LP acquired a new position in Jasper Therapeutics during the 2nd quarter worth about $78,000. Voleon Capital Management LP bought a new stake in shares of Jasper Therapeutics in the 3rd quarter valued at about $50,000. Finally, Goldman Sachs Group Inc. increased its stake in shares of Jasper Therapeutics by 11.2% in the first quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock valued at $1,005,000 after buying an additional 23,453 shares during the period. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.